Related Experiment Video
Updated: Aug 8, 2026

09:59
An “All-laser” Endothelial Transplant
Published on: July 6, 2015
Photorefractive keratectomy for low-to-moderate myopia and astigmatism with a small-beam, tracker-directed excimer
M B McDonald1, M R Deitz, J M Frantz
1Refractive Surgery Center of the South, Eye, Ear, Nose and Throat Hospital, New Orleans, Louisiana, USA.
Ophthalmology
|August 12, 1999
Summary
This study shows the LADARVision excimer laser system is safe and effective for myopia and astigmatism correction. Patients achieved excellent vision and refractive stability with minimal complications.
Area of Science:
- Ophthalmology
- Refractive Surgery
- Excimer Laser Technology
Background:
- Myopia and astigmatism are common refractive errors impacting visual acuity.
- Photorefractive keratectomy (PRK) is a surgical option for correcting these conditions.
- Advancements in excimer laser systems aim to improve safety and efficacy.
Purpose of the Study:
- To evaluate the safety and effectiveness of the Autonomous Technologies Corporation LADARVision excimer laser system.
- To assess its performance in correcting myopia and astigmatism via photorefractive keratectomy.
Main Methods:
- A multicenter, prospective, noncomparative case series involving 678 eyes.
- Treatments were performed using specific ablation zones for spherical myopia and myopic astigmatism.
- Key outcome measures included visual acuity, refractive error, corneal haze, and endothelial cell changes.
Main Results:
- High rates of uncorrected visual acuity (UCVA) of 20/40 or better (93.4-98.1%) and 20/20 or better (61.2-72%) were achieved.
- Excellent refractive outcomes with 73.9-76.4% within 0.50 D of target correction.
- Refractive stability was observed within 3-6 months, with no significant loss of best spectacle-corrected visual acuity (BSCVA) or endothelial cell density.
Conclusions:
- The LADARVision excimer laser system demonstrates safety and effectiveness for correcting myopia and astigmatism up to 10 diopters.
- The procedure resulted in early refractive stability and high patient satisfaction.
- Minimal corneal haze and no adverse endothelial cell changes were noted at 12 months.

